US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DOGWOOD THERAPEUTICS INC

3.17

0.0000

Post-market: 3.170.00000.00%16:07 EST

Volume:12.58K

Turnover:39.46K

Market Cap:101.70M

PE:-0.13

High:3.17

Open:3.14

Low:3.05

Close:3.17

52wk High:14.69

52wk Low:2.60

Shares:32.08M

Float Shares:7.00M

Volume Ratio:0.27

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-24.9248

EPS(LYR):-12.5160

ROE:-930.96%

ROA:-42.04%

PB:-3.08

PE(LYR):-0.25

Loading ...

Overview Company News Filings

Dogwood Therapeutics Reaches 50% Enrollment in Phase 2b Halneuron Trial for Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics Inc - Halt-Cinp Trial Results Expected in Q3 2026

THOMSON REUTERS

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2B Trial, Top Line Results Anticipated in Q3 2026

THOMSON REUTERS

Dogwood Therapeutics Inc - Commencing Dosing Patients in Forthcoming SP16 Phase 1B Study by Mid-2026

THOMSON REUTERS

Dogwood Therapeutics: to Submit End of Halneuron Phase 2 Summary, Manufacturing Plans & Phase 3 Clinical Development Plans to FDA Towards End of 2026

THOMSON REUTERS

Dogwood Therapeutics Inc - in 2026, Progressing Halneuron Through Phase 2B Development With Final Phase 2B Data Projected for Release in Q3 2026

THOMSON REUTERS

Dogwood Therapeutics Advances Halneuron Phase 2b Trial and Expands Pipeline for Cancer-Related Pain Therapies

Dogwood files to sell 6.43M shares of common stock for holders

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2B Development

THOMSON REUTERS

Dogwood Therapeutics Announces Warrant and Share Rights Issuance in $26.8 Million Financing

Press Release: Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron(R) Through Phase 2b Development

CK Life Sciences Subsidiary Dogwood Therapeutics Reports Positive Interim Results in Pain Drug Trial

Dogwood Therapeutics Reports Positive Interim Phase 2b Results for Halneuron in Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics Inc - Expects Top-Line Results in Q3 2026

THOMSON REUTERS

BRIEF-Dogwood Therapeutics Inc - Enters Equity Distribution Agreement With Northland Securities - SEC Filing

Dogwood Therapeutics Inc - to Sell Shares Worth up to $8.56 Mln - SEC Filing

THOMSON REUTERS

Dogwood Therapeutics Inc. held special shareholder meeting

Dogwood Therapeutics Q3 EPS USD -8.2

Dogwood Therapeutics Enrolls First 100 Patients in Halneuron Phase 2b Neuropathy Trial

Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DWTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DWTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":3.17,"timestamp":1770411600000,"preClose":3.17,"halted":0,"volume":12581,"hourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.17,"latestTime":"16:07 EST","volume":9,"amount":27.094,"timestamp":1770412062328,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":6995900,"shares":32082464,"eps":-24.9248,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST","open":3.14,"high":3.17,"low":3.05,"amount":39455.2257,"amplitude":0.037855,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-24.9248,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":3.17,"preHourTrading":{"tag":"盘前","latestPrice":3.2796,"preClose":3.17,"latestTime":"09:08 EST","volume":71,"amount":224.2150038,"timestamp":1770386935669,"change":0.1096,"changeRate":0.034574,"amplitude":0.138801},"postHourTrading":{"tag":"盘后","latestPrice":3.17,"preClose":3.17,"latestTime":"16:07 EST","volume":9,"amount":27.094,"timestamp":1770412062328,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.272772},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","floatShares":6995900,"roa":"-42.04%","roe":"-930.96%","lyrEps":-12.516033,"volumeRatio":0.272772,"shares":32082464,"dividePrice":0,"high":3.17,"amplitude":0.037855,"preClose":3.17,"low":3.05,"week52Low":2.6,"pbRate":"-3.08","week52High":14.69,"institutionHeld":0,"latestPrice":3.17,"eps":-24.9248,"divideRate":0,"volume":12581,"delay":0,"ttmEps":-24.9248,"open":3.14,"prevYearClose":4.16,"prevWeekClose":2.79,"prevMonthClose":2.79,"prevQuarterClose":4.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DWTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"DWTX","fiscalQuarterEnding":"2025/09","expectedEps":-1.23,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-8.2},{"market":"US","date":"2025-08-13","symbol":"DWTX","fiscalQuarterEnding":"2025/06","expectedEps":-1.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-1.99},{"market":"US","date":"2025-05-08","symbol":"DWTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-4.21},{"market":"US","date":"2025-03-31","symbol":"DWTX","fiscalQuarterEnding":"2024/12","expectedEps":-1.49,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-6.29},{"market":"US","date":"2024-10-09","symbol":"DWTX","defaultRemindTime":1728480600000,"type":"split","dateTimestamp":1728446400000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DWTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DWTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1745384400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DWTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DWTX","date":"2026-02-05","current":-0.127183,"percent":0.100304,"low":-5.30677,"twenty":-1.355562,"median":-0.565465,"eighty":-0.407031,"high":-0.31572,"avg":-1.019172,"sd":1.028646,"marketCap":98813989},"quantilePoints":[{"date":"2024-10-11","current":-0.88829,"twenty":-0.871777,"median":-0.847007,"eighty":-0.822237,"marketCap":4156676},{"date":"2024-10-18","current":-1.14168,"twenty":-1.243599,"median":-1.14168,"eighty":-0.919038,"marketCap":5342394},{"date":"2024-10-25","current":-1.352393,"twenty":-1.244175,"median":-1.155915,"eighty":-1.05342,"marketCap":6328406},{"date":"2024-10-31","current":-1.184386,"twenty":-1.27834,"median":-1.174407,"eighty":-1.098974,"marketCap":5542234},{"date":"2024-11-08","current":-1.035557,"twenty":-1.27834,"median":-1.184386,"eighty":-1.098974,"marketCap":5928592},{"date":"2024-11-15","current":-0.74467,"twenty":-1.269799,"median":-1.17156,"eighty":-0.88829,"marketCap":4263257},{"date":"2024-11-22","current":-0.6306,"twenty":-1.266952,"median":-1.124597,"eighty":-0.74467,"marketCap":3610202},{"date":"2024-11-29","current":-0.558465,"twenty":-1.264674,"median":-1.042032,"eighty":-0.629204,"marketCap":3197227},{"date":"2024-12-06","current":-0.532869,"twenty":-1.261826,"median":-0.94447,"eighty":-0.591959,"marketCap":3050687},{"date":"2024-12-13","current":-0.560792,"twenty":-1.247591,"median":-0.805175,"eighty":-0.586099,"marketCap":3210548},{"date":"2024-12-20","current":-0.53985,"twenty":-1.196344,"median":-0.717909,"eighty":-0.564981,"marketCap":3090652},{"date":"2024-12-27","current":-0.609658,"twenty":-1.179261,"median":-0.679489,"eighty":-0.564515,"marketCap":3490306},{"date":"2025-01-03","current":-0.584061,"twenty":-1.174695,"median":-0.665504,"eighty":-0.565461,"marketCap":3343766},{"date":"2025-01-10","current":-0.553811,"twenty":-1.172405,"median":-0.646888,"eighty":-0.565454,"marketCap":3170583},{"date":"2025-01-17","current":-0.449099,"twenty":-1.164457,"median":-0.623619,"eighty":-0.558465,"marketCap":2571103},{"date":"2025-01-24","current":-3.106463,"twenty":-1.170151,"median":-0.6306,"eighty":-0.558465,"marketCap":17784576},{"date":"2025-01-31","current":-2.969173,"twenty":-1.244175,"median":-0.653869,"eighty":-0.558465,"marketCap":16998591},{"date":"2025-02-07","current":-2.748114,"twenty":-1.269799,"median":-0.667831,"eighty":-0.560792,"marketCap":15733022},{"date":"2025-02-14","current":-1.561376,"twenty":-1.386529,"median":-0.691147,"eighty":-0.563119,"marketCap":8938914},{"date":"2025-02-21","current":-1.36824,"twenty":-1.406654,"median":-0.738827,"eighty":-0.564981,"marketCap":7833206},{"date":"2025-02-28","current":-1.095988,"twenty":-1.389852,"median":-0.805175,"eighty":-0.565476,"marketCap":6274558},{"date":"2025-03-07","current":-1.030834,"twenty":-1.384928,"median":-0.926984,"eighty":-0.569177,"marketCap":5901548},{"date":"2025-03-14","current":-1.798723,"twenty":-1.448286,"median":-1.000651,"eighty":-0.577546,"marketCap":10297735},{"date":"2025-03-21","current":-1.056947,"twenty":-1.431015,"median":-0.999453,"eighty":-0.58313,"marketCap":13053004},{"date":"2025-03-28","current":-0.925409,"twenty":-1.421838,"median":-0.979572,"eighty":-0.584992,"marketCap":11428545},{"date":"2025-04-04","current":-0.646858,"twenty":-1.406654,"median":-0.930825,"eighty":-0.586099,"marketCap":7988515},{"date":"2025-04-11","current":-0.317141,"twenty":-1.389852,"median":-0.88829,"eighty":-0.58313,"marketCap":3916603},{"date":"2025-04-17","current":-0.402359,"twenty":-1.385328,"median":-0.805724,"eighty":-0.565469,"marketCap":4969023},{"date":"2025-04-25","current":-0.61055,"twenty":-1.374755,"median":-0.785584,"eighty":-0.565469,"marketCap":7540127},{"date":"2025-05-02","current":-0.578189,"twenty":-1.358732,"median":-0.74467,"eighty":-0.568254,"marketCap":7140474},{"date":"2025-05-09","current":-0.374989,"twenty":-1.330168,"median":-0.724741,"eighty":-0.565469,"marketCap":8714743},{"date":"2025-05-16","current":-0.451467,"twenty":-1.293145,"median":-0.691147,"eighty":-0.558465,"marketCap":10492092},{"date":"2025-05-23","current":-0.435842,"twenty":-1.273215,"median":-0.667831,"eighty":-0.549157,"marketCap":10128978},{"date":"2025-05-30","current":-0.43502,"twenty":-1.26866,"median":-0.661674,"eighty":-0.542709,"marketCap":10109867},{"date":"2025-06-06","current":-0.424679,"twenty":-1.265813,"median":-0.656935,"eighty":-0.524492,"marketCap":9335860},{"date":"2025-06-13","current":-0.450325,"twenty":-1.262965,"median":-0.649201,"eighty":-0.469065,"marketCap":9899643},{"date":"2025-06-20","current":-0.417289,"twenty":-1.258453,"median":-0.635392,"eighty":-0.460532,"marketCap":9173414},{"date":"2025-06-27","current":-0.414681,"twenty":-1.246626,"median":-0.62674,"eighty":-0.450325,"marketCap":9116080},{"date":"2025-07-03","current":-0.417289,"twenty":-1.244175,"median":-0.623619,"eighty":-0.448744,"marketCap":9173414},{"date":"2025-07-11","current":-0.433807,"twenty":-1.191392,"median":-0.616057,"eighty":-0.435137,"marketCap":9536528},{"date":"2025-07-18","current":-0.413812,"twenty":-1.184386,"median":-0.61055,"eighty":-0.430908,"marketCap":9096969},{"date":"2025-07-25","current":-0.411204,"twenty":-1.175845,"median":-0.606188,"eighty":-0.428591,"marketCap":9039635},{"date":"2025-08-01","current":-0.420332,"twenty":-1.175104,"median":-0.602999,"eighty":-0.424679,"marketCap":9240303},{"date":"2025-08-08","current":-0.425287,"twenty":-1.172969,"median":-0.594948,"eighty":-0.422505,"marketCap":9349238},{"date":"2025-08-15","current":-0.380049,"twenty":-1.170151,"median":-0.588976,"eighty":-0.421636,"marketCap":9402749},{"date":"2025-08-22","current":-0.381594,"twenty":-1.165796,"median":-0.584643,"eighty":-0.419028,"marketCap":9440972},{"date":"2025-08-29","current":-0.370394,"twenty":-1.14168,"median":-0.579408,"eighty":-0.417298,"marketCap":9163858},{"date":"2025-09-05","current":-0.386229,"twenty":-1.128014,"median":-0.578189,"eighty":-0.417289,"marketCap":9555640},{"date":"2025-09-12","current":-0.378257,"twenty":-1.116602,"median":-0.565465,"eighty":-0.414688,"marketCap":9358411},{"date":"2025-09-19","current":-0.371892,"twenty":-1.1021,"median":-0.560792,"eighty":-0.413812,"marketCap":9200934},{"date":"2025-09-26","current":-0.394726,"twenty":-1.096585,"median":-0.556138,"eighty":-0.410856,"marketCap":9765864},{"date":"2025-10-03","current":-0.495918,"twenty":-1.064755,"median":-0.553811,"eighty":-0.413012,"marketCap":12269441},{"date":"2025-10-10","current":-0.519049,"twenty":-1.045015,"median":-0.552647,"eighty":-0.413742,"marketCap":12841707},{"date":"2025-10-17","current":-0.55705,"twenty":-1.036852,"median":-0.55705,"eighty":-0.413812,"marketCap":13781903},{"date":"2025-10-24","current":-0.520902,"twenty":-1.035502,"median":-0.552647,"eighty":-0.413812,"marketCap":12887570},{"date":"2025-10-31","current":-0.61637,"twenty":-1.031765,"median":-0.55705,"eighty":-0.414507,"marketCap":15249527},{"date":"2025-11-07","current":-0.481974,"twenty":-1.007156,"median":-0.555431,"eighty":-0.414681,"marketCap":11924442},{"date":"2025-11-14","current":-0.327725,"twenty":-1.000768,"median":-0.549157,"eighty":-0.413742,"marketCap":12520664},{"date":"2025-11-21","current":-0.357136,"twenty":-0.998735,"median":-0.545565,"eighty":-0.409242,"marketCap":13644313},{"date":"2025-11-28","current":-0.391355,"twenty":-0.987046,"median":-0.544503,"eighty":-0.403493,"marketCap":14951645},{"date":"2025-12-05","current":-0.368541,"twenty":-0.971236,"median":-0.53985,"eighty":-0.398837,"marketCap":14080014},{"date":"2025-12-12","current":-4.995522,"twenty":-0.987046,"median":-0.53985,"eighty":-0.39658,"marketCap":190852899},{"date":"2025-12-19","current":-4.746524,"twenty":-1.032696,"median":-0.544503,"eighty":-0.398429,"marketCap":181339982},{"date":"2025-12-26","current":-3.40816,"twenty":-1.050981,"median":-0.545001,"eighty":-0.398837,"marketCap":130208053},{"date":"2026-01-02","current":-3.236974,"twenty":-1.111477,"median":-0.549157,"eighty":-0.39905,"marketCap":123667922},{"date":"2026-01-09","current":-2.451074,"twenty":-1.16928,"median":-0.552647,"eighty":-0.399948,"marketCap":93642777},{"date":"2026-01-16","current":-2.351299,"twenty":-1.182678,"median":-0.557977,"eighty":-0.400578,"marketCap":89830899},{"date":"2026-01-23","current":-2.578032,"twenty":-1.247239,"median":-0.558465,"eighty":-0.402359,"marketCap":98493164},{"date":"2026-01-30","current":-2.435274,"twenty":-1.269799,"median":-0.561956,"eighty":-0.404249,"marketCap":93039145},{"date":"2026-02-05","current":-2.586429,"twenty":-1.355562,"median":-0.565465,"eighty":-0.407031,"marketCap":98813989}],"updateTime":1770417030597},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DWTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608864619","title":"Dogwood Therapeutics Reaches 50% Enrollment in Phase 2b Halneuron Trial for Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2608864619","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608864619?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:31","pubTimestamp":1770039068,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. announced that it has surpassed 50% enrollment in its ongoing Phase 2b HALT-CINP trial evaluating Halneuron for the treatment of chemotherapy-induced neuropathic pain. Interim analysis of 97 patients showed that Halneuron demonstrated separation from placebo in pain improvement over a four-week study period. The company reported a low early termination rate among enrolled patients, suggesting favorable tolerability. Top line results from the study are expected in the third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 02, 2026, and is solely responsible for the information ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL7CqqnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","BK4585","LU0314104364.USD","NDAQ","DWTX","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2608646938","title":"Dogwood Therapeutics Inc - Halt-Cinp Trial Results Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608646938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608646938?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:30","pubTimestamp":1770039002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KCDZV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2608645218","title":"Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2B Trial, Top Line Results Anticipated in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608645218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608645218?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:30","pubTimestamp":1770039002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KCDZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2604116864","title":"Dogwood Therapeutics Inc - Commencing Dosing Patients in Forthcoming SP16 Phase 1B Study by Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116864?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:34","pubTimestamp":1768916097,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0KJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2604116823","title":"Dogwood Therapeutics: to Submit End of Halneuron Phase 2 Summary, Manufacturing Plans & Phase 3 Clinical Development Plans to FDA Towards End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116823?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:34","pubTimestamp":1768916097,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0KJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2604115068","title":"Dogwood Therapeutics Inc - in 2026, Progressing Halneuron Through Phase 2B Development With Final Phase 2B Data Projected for Release in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115068?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:34","pubTimestamp":1768916097,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2604115048","title":"Dogwood Therapeutics Advances Halneuron Phase 2b Trial and Expands Pipeline for Cancer-Related Pain Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115048","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115048?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:31","pubTimestamp":1768915904,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc.  announced progress in its pipeline targeting cancer-related pain and neuropathy, according to a shareholder letter from CEO Greg Duncan. In 2025, the company recruited over 100 patients for the Halneuron Phase 2b Chemotherapy Induced Pain  Study, enabling an interim analysis to determine final study sample size and optimal analysis methodology. The company also secured a royalty-free, global license for SP16 IV, a potential treatment for neuropathy and inflammation caused by cancer chemotherapy, with its Phase 1b study fully funded by a development grant from the National Cancer Institute. Additionally, Dogwood Therapeutics advanced a synthesized version of Halneuron for Phase 3 development, aiming to reduce manufacturing costs and improve yields, and filed for new intellectual property protection that could extend Halneuron’s protection to 2046. Key 2026 goals include releasing final Phase 2b data for Halneuron in Q3 2026 and submitting end of Phase 2 summar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL28cW0K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2603393656","title":"Dogwood files to sell 6.43M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2603393656","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603393656?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:25","pubTimestamp":1768512314,"startTime":"0","endTime":"0","summary":"16:22 EST Dogwood (DWTX) files to sell 6.43M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mark...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dogwood-files-to-sell-6-43m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dogwood-files-to-sell-6-43m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2602654819","title":"Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2B Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2602654819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602654819?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:33","pubTimestamp":1768224794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","00775","DWTX","BK1569","BK1161"],"gpt_icon":0},{"id":"2602489145","title":"Dogwood Therapeutics Announces Warrant and Share Rights Issuance in $26.8 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602489145","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602489145?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224633,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor for a financing of up to approximately $26.8 million. The financing includes a registered direct offering and a concurrent private placement, issuing an aggregate of 4,386,037 shares of common stock or pre-funded warrants, and warrants to purchase up to 4,386,037 shares of common stock. The company has agreed to file one or more registration statements with the SEC to cover the resale of the shares issuable upon exercise of the pre-funded warrants and warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL65hvLm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","SG9999014039.USD","DWTX","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2602465548","title":"Press Release: Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron(R) Through Phase 2b Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2602465548","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602465548?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224600,"startTime":"0","endTime":"0","summary":"The Registered Offering consists of the issuance and sale of 2,338,948 shares of common stock, and the Private Offering consists of the issuance and sale of pre-funded warrants to purchase 2,047,089 shares of common stock and warrants to purchase up to 4,386,037 shares of common stock.Greg Duncan, Chairman and CEO of DWTX, commented: \"We plan to utilize the net proceeds from the Offering to advance development of Halneuron through the ongoing Phase 2b final data readout, while also pursuing strategic opportunities to further strengthen the Company's research portfolio. We are executing with determination to advance the standard of care for patients suffering from chemotherapy induced pain and neuropathy, conditions for which there are no FDA approved treatments. This transaction represents a strong endorsement of our two first-in-class development candidates, Halneuron and SP16, our research progress, growing IP portfolio and the exceptional talent we've assembled. Today's offering pro","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU1974910355.USD","BK4007","LU0097036916.USD","BK4559","LU0545562505.USD","IE00BKDWB100.SGD","IE00BQXX3D17.EUR","LU2720916845.USD","LU0426412945.USD","V","LU0310800379.SGD","LU0965508806.USD","LU1852331112.SGD","LU0215105999.USD","BK4097","LU0683600562.USD","IE00B19Z9505.USD","PRGS","LU1670628061.USD","LU1429558221.USD","BK4139","LU0170899867.USD","LENZ","LU0642271901.SGD","LU0957808578.USD","LU0823421416.USD","SGXZ51526630.SGD","IE00B19Z8X17.USD","IE00B1XK9C88.USD","BK4227","LU0048584097.USD","LU1791710582.SGD","LU1935042215.USD","LU0823434740.USD","LU1363072403.SGD","SGXZ99366536.SGD","LU0096362180.USD","DWTX","LU0354030511.USD","LU0251132253.USD","LU1691799644.USD","LU0234570918.USD","R","LU2111349929.HKD","SG9999014906.USD","LU0353189763.USD","SG9999014898.SGD","LU2471134879.HKD","LU0950375773.USD"],"gpt_icon":0},{"id":"2593459329","title":"CK Life Sciences Subsidiary Dogwood Therapeutics Reports Positive Interim Results in Pain Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459329","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593459329?lang=en_us&edition=fundamental","pubTime":"2025-12-23 07:51","pubTimestamp":1766447505,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CK Life Sciences International  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL2JF4F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","DWTX","BK1569","00775"],"gpt_icon":0},{"id":"2593436305","title":"Dogwood Therapeutics Reports Positive Interim Phase 2b Results for Halneuron in Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2593436305","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593436305?lang=en_us&edition=fundamental","pubTime":"2025-12-22 23:15","pubTimestamp":1766416510,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. announced positive interim results from its ongoing Phase 2b clinical trial evaluating Halneuron in patients with chemotherapy-induced neuropathic pain . According to the company, an independent statistical review committee found that patients treated with Halneuron showed separation from placebo in pain improvement assessments over the four-week study period. The interim analysis was based on data from 97 patients who had completed treatment. The company reported a study dropout rate of approximately 4.4%, which it noted is lower than rates typically observed with other FDA-approved chronic pain medications. Dogwood Therapeutics expects to present top-line results from the trial in the third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDLqt4nr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","SG9999014039.USD","LU2210150020.SGD","BK4585","DWTX","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2593436535","title":"Dogwood Therapeutics Inc - Expects Top-Line Results in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593436535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593436535?lang=en_us&edition=fundamental","pubTime":"2025-12-22 23:15","pubTimestamp":1766416500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA1GJWL4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2587378447","title":"BRIEF-Dogwood Therapeutics Inc - Enters Equity Distribution Agreement With Northland Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587378447","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587378447?lang=en_us&edition=fundamental","pubTime":"2025-11-29 04:33","pubTimestamp":1764362038,"startTime":"0","endTime":"0","summary":"BRIEF-Dogwood Therapeutics Inc - Enters Equity Distribution Agreement With Northland Securities - SEC FilingDogwood Therapeutics Inc DWTX.O:DOGWOOD THERAPEUTICS INC - ENTERS EQUITY DISTRIBUTION AGREEMENT WITH NORTHLAND SECURITIES - SEC FILINGDOGWOOD THERAPEUTICS INC - TO SELL SHARES WORTH UP TO $8.56 MILLION - SEC FILINGSource text: [ID:n0001104659-25-116865]Further company coverage: DWTX.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2587734046","title":"Dogwood Therapeutics Inc - to Sell Shares Worth up to $8.56 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587734046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587734046?lang=en_us&edition=fundamental","pubTime":"2025-11-29 03:19","pubTimestamp":1764357556,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40L8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2585140483","title":"Dogwood Therapeutics Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2585140483","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585140483?lang=en_us&edition=fundamental","pubTime":"2025-11-22 02:02","pubTimestamp":1763748125,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. held a special meeting of stockholders on November 21, 2025. Stockholders approved the Second Amended and Restated Equity Incentive Plan, which increases the number of shares reserved for issuance. Approval was also granted for the potential issuance of common stock upon conversion of both the Series A and Series A-2 Non-Voting Convertible Preferred Stock. The adjournment of the special meeting to a later date or dates, if necessary or appropriate, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL2bX39h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2584099926","title":"Dogwood Therapeutics Q3 EPS USD -8.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2584099926","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584099926?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:55","pubTimestamp":1763571340,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Dogwood Therapeutics Q3 net income USD -15.7 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202513:05:00.123 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2ZBlq9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2582736445","title":"Dogwood Therapeutics Enrolls First 100 Patients in Halneuron Phase 2b Neuropathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582736445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582736445?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:45","pubTimestamp":1762868717,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. announced the enrollment of the first 100 patients in its ongoing Phase 2b HALT-CINP clinical trial evaluating Halneuron for chemotherapy-induced neuropathic pain . The study is assessing the safety and effectiveness of Halneuron compared to placebo in cancer patients with neuropathy resulting from previous platinum or taxane-based chemotherapy. Participants receive eight subcutaneous doses over 14 days, with follow-up at 28 days. The primary endpoint is the change in weekly average daily pain intensity scores from baseline to week four. An interim sample size analysis is scheduled for the fourth quarter of 2025, and final trial data are expected by mid-2026. Results from the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDLCf3wS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2582656358","title":"Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582656358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582656358?lang=en_us&edition=fundamental","pubTime":"2025-11-08 23:40","pubTimestamp":1762616412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT – Research Report) and Dogwood Therap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-altimmune-alt-dogwood-therapeutics-dwtx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-altimmune-alt-dogwood-therapeutics-dwtx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","DWTX","LABU","BK4581","ALT","BK4139","BK4585","BK4588","BK4599","HCSG","XLV","BK4112","BK4137","LU0029874061.USD","LU1878469433.USD","XBI"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}